Dr. Rebecca S. Overbury, MD

Dr. Overbury practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Overbury's NPI, 1861767048, was assigned on March 20, 2012. Dr. Overbury graduated from University of Tennessee, Hsc, College of Medicine in 2012. Dr. Overbury holds Utah license 8790944-1205.

Dr. Overbury's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Overbury's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Overbury is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Overbury to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Overbury practices, 4 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Overbury's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Overbury is licensed in Utah.

CMS data shows 70 Medicare services from Dr. Overbury across 2 procedure codes in 2024, for 54 Medicare patients. Medicare paid $2,429 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 54 Medicare patients who saw Dr. Overbury in 2024. The largest group is 65 to 74, with 22 patients. 72% of them have arthritis, and 59% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Overbury's median patient age at 60, with 68% women.

In 2024, Dr. Overbury wrote 396 Medicare Part D claims for 63 patients. 85% of them were for generic drugs. CMS names the drug for 259 of them, across 11 drugs with 11 or more claims each, at $347,515 in total drug cost. In 2023, CMS named 359 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Overbury for performance year 2024, reported as part of a group. Dr. Overbury accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Overbury as offering telehealth.

Dmand AI links 11 papers to Dr. Overbury, published from 2015 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Capillaries, Microscopic Angioscopy and Nails. Dr. Overbury has published most often in J Rheumatol. Dr. Overbury's most frequent co-authors are Tracy Minan Frech, MD, Nicole Galgoul Bitencourt, MD and Joyce C. Chang, MD.

CMS Open Payments shows 1 general payment to Dr. Overbury from 1 drug or device company in 2016. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $102.

Dr. Overbury graduated from University of Tennessee, Hsc, College of Medicine in 2012.